Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents
- 2 January 2021
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 32, 115960
- https://doi.org/10.1016/j.bmc.2020.115960
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical ModelsScience Translational Medicine, 2014
- Over-expression of COX-2 mRNA in colorectal cancerBMC Gastroenterology, 2014
- Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cellsBioorganic & Medicinal Chemistry Letters, 2011
- The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human MalignanciesInternational Journal of Cell Biology, 2010
- The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironmentCarcinogenesis: Integrative Cancer Research, 2009
- The role of COX-2 inhibition in breast cancer treatment and preventionSeminars in Oncology, 2004
- COX-2 inhibitors in cancer treatment and prevention, a recent developmentAnti-Cancer Drugs, 2002
- Cytoplasmic induction and over‐expression of cyclooxygenase‐2 in human prostate cancer: implications for prevention and treatmentBJU International, 2000
- The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesisGastroenterology, 2000
- Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesionsCarcinogenesis: Integrative Cancer Research, 2000